ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 278 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $344,997,205 | -24.5% | 12,839,494 | +0.2% | 0.01% | -23.1% |
| Q2 2023 | $456,845,893 | +41.5% | 12,811,158 | +0.8% | 0.01% | +30.0% |
| Q1 2023 | $322,854,345 | -37.4% | 12,710,801 | -0.0% | 0.01% | -37.5% |
| Q4 2022 | $515,563,757 | +29.0% | 12,711,138 | +5.2% | 0.02% | +14.3% |
| Q3 2022 | $399,513,000 | -7.6% | 12,088,088 | -1.6% | 0.01% | 0.0% |
| Q2 2022 | $432,535,000 | -22.6% | 12,284,473 | +1.1% | 0.01% | -6.7% |
| Q1 2022 | $559,014,000 | -29.8% | 12,155,084 | +1.2% | 0.02% | -25.0% |
| Q4 2021 | $796,135,000 | +6.8% | 12,008,063 | +0.6% | 0.02% | -4.8% |
| Q3 2021 | $745,531,000 | -25.9% | 11,941,845 | -1.7% | 0.02% | -25.0% |
| Q2 2021 | $1,006,221,000 | +17.6% | 12,149,503 | -5.8% | 0.03% | +12.0% |
| Q1 2021 | $855,480,000 | -11.3% | 12,901,227 | +2.7% | 0.02% | -19.4% |
| Q4 2020 | $963,970,000 | +78.2% | 12,563,132 | +0.0% | 0.03% | +55.0% |
| Q3 2020 | $540,850,000 | -3.3% | 12,560,369 | -3.0% | 0.02% | -9.1% |
| Q2 2020 | $559,524,000 | +56.4% | 12,954,928 | +4.2% | 0.02% | +29.4% |
| Q1 2020 | $357,658,000 | -54.4% | 12,431,618 | +0.6% | 0.02% | -43.3% |
| Q4 2019 | $784,054,000 | +85.2% | 12,360,958 | -17.7% | 0.03% | +66.7% |
| Q3 2019 | $423,283,000 | +7.6% | 15,020,650 | +1.2% | 0.02% | +5.9% |
| Q2 2019 | $393,313,000 | +180.9% | 14,841,966 | +94.5% | 0.02% | +183.3% |
| Q1 2019 | $140,030,000 | +56.9% | 7,631,074 | +6.2% | 0.01% | +20.0% |
| Q4 2018 | $89,232,000 | -34.4% | 7,184,621 | +1.3% | 0.01% | -16.7% |
| Q3 2018 | $135,964,000 | +41.1% | 7,092,504 | +0.1% | 0.01% | +50.0% |
| Q2 2018 | $96,342,000 | +292.5% | 7,083,926 | +108.1% | 0.00% | +300.0% |
| Q1 2018 | $24,543,000 | +142.6% | 3,403,940 | +23.8% | 0.00% | – |
| Q4 2017 | $10,115,000 | -18.3% | 2,748,828 | -3.9% | 0.00% | -100.0% |
| Q3 2017 | $12,380,000 | +210.0% | 2,859,169 | +16.0% | 0.00% | – |
| Q2 2017 | $3,993,000 | -61.4% | 2,464,607 | -55.9% | 0.00% | -100.0% |
| Q1 2017 | $10,334,000 | +129075.0% | 5,585,632 | +108866.7% | 0.00% | – |
| Q4 2016 | $8,000 | -82.2% | 5,126 | -15.5% | 0.00% | – |
| Q3 2016 | $45,000 | +55.2% | 6,064 | +11.1% | 0.00% | – |
| Q2 2016 | $29,000 | – | 5,457 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,264 | $54,392,000 | 33.22% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $216,228,000 | 28.00% |
| L1 Capital Pty Ltd | 296,024 | $19,629,000 | 4.93% |
| Aquilo Capital Management, LLC | 407,926 | $27,050,000 | 4.89% |
| Evolutionary Tree Capital Management, LLC | 72,948 | $4,837,000 | 2.86% |
| ACUTA CAPITAL PARTNERS, LLC | 108,000 | $7,161,000 | 2.58% |
| First Light Asset Management, LLC | 536,836 | $35,598,000 | 2.36% |
| Parkman Healthcare Partners LLC | 70,089 | $4,648,000 | 1.08% |
| Hood River Capital Management LLC | 357,082 | $23,678,000 | 0.76% |
| Vanguard Capital Wealth Advisors | 11,099 | $703,565,000 | 0.60% |